The shares of Moderna Inc. (MRNA) have recorded the market capitalization of 39.99B

The stock of Moderna Inc. (NASDAQ:MRNA) last traded at $106.74, up 2.50% from the previous session.

Data from the available sources indicates that Moderna Inc. (NASDAQ:MRNA) is covered by 24 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $430.00 and a low of $66.00, we find $167.00. Given the previous closing price of $104.14, this indicates a potential upside of 60.36 percent. MRNA stock price is now -5.29% away from the 50-day moving average and -25.73% away from the 200-day moving average. The market capitalization of the company currently stands at $39.99B.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

Sponsored

In total, 10 analysts have assigned it a hold rating, and 10 have given it a buy rating. Brokers who have rated the stock have averaged $179.31 as their price target over the next twelve months.

With the price target reduced from $145 to $125, TD Cowen Downgraded its rating from Outperform to Market Perform for Moderna Inc. (NASDAQ: MRNA).

In other news, Hoge Stephen, President sold 15,000 shares of the company’s stock on Sep 15. The stock was sold for $1,694,850 at an average price of $112.99. Upon completion of the transaction, the President now directly owns 1,574,187 shares in the company, valued at $168.03 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 13, Director AFEYAN NOUBAR sold 15,000 shares of the business’s stock. A total of $1,645,522 was realized by selling the stock at an average price of $109.70. This leaves the insider owning 2,221,931 shares of the company worth $237.17 million. Insiders disposed of 3,439,448 shares of company stock worth roughly $367.13 million over the past 1 year. A total of 2.40% of the company’s stock is owned by insiders.

There have been several recent changes in the stakes of large investors in MRNA stock. A new stake in Moderna Inc. shares was purchased by MN SERVICES VERMOGENSBEHEER B.V. during the first quarter worth $16,673,000. LINGOTTO INVESTMENT MANAGEMENT LLP invested $14,207,000 in shares of MRNA during the first quarter. In the first quarter, GTS SECURITIES LLC acquired a new stake in Moderna Inc. valued at approximately $12,498,000. ABEILLE ASSET MANAGEMENT SA acquired a new stake in MRNA for approximately $9,829,000. CTC LLC purchased a new stake in MRNA valued at around $8,363,000 in the second quarter. In total, there are 1,464 active investors with 65.90% ownership of the company’s stock.

With an opening price of $102.31 on Tuesday morning, Moderna Inc. (NASDAQ: MRNA) set off the trading day. During the past 12 months, Moderna Inc. has had a low of $95.02 and a high of $217.25. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 3.40, and a quick ratio of 3.20. The fifty day moving average price for MRNA is $112.38 and a two-hundred day moving average price translates $143.37 for the stock.

The latest earnings results from Moderna Inc. (NASDAQ: MRNA) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$3.62, beating analysts’ expectations of -$4.04 by 0.42. This compares to $5.24 EPS in the same period last year. The net profit margin was 11.30% and return on equity was 6.60% for MRNA. The company reported revenue of $344.0 million for the quarter, compared to $4.75 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -92.76 percent. For the current quarter, analysts expect MRNA to generate $1.6B in revenue.

Moderna Inc.(MRNA) Company Profile

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Related Posts